Device Trial Radar · NCT06594705
The JenaValve ALIGN-AR LVAD Registry
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
50
Actual
Start
Dec 9, 2024
Primary completion
Aug 9, 2026
Study completion Aug 2027
Sponsor
- Lead sponsor
- JenaValve Technology, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and effectiveness of the JenaValve Trilogy™ Heart Valve System for transcatheter aortic valve replacement (TAVR) in subjects with continuous flow left ventricular assist devices (cfLVAD) and clinically significant aortic regurgitation (AR) who are indicated for TAVR
Conditions
- Aortic Regurgitation
- Aortic Valve Insufficiency
- Aortic Insufficiency
- Aortic Valve Disease
- Left Ventricular Dysfunction
Interventions
JenaValve Trilogy Heart Valve SystemDevice
TAVR with JenaValve Trilogy Heart Valve System
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Efficacy Endpoint: Modified VARC-3 Device SuccessTime frame: 30 days
- Primary Safety Endpoint: VARC-3 Early Safety CompositeTime frame: 30 days
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center
Los Angeles, California
Sutter Health
San Francisco, California
Medstar Washington Hospital Center
Washington D.C., District of Columbia
11 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.